BioCentury | Dec 12, 2011
Product Development

Back for seconds

...pore ( mPTP ). The other is TIK-201 , a histone deacetylase (HDAC) inhibitor from Tikvah Therapeutics Inc....
...Corp. (NASDAQ:RGEN), Waltham, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel Switzerland SMA Foundation , New York, N.Y. Tikvah Therapeutics Inc....
BioCentury | Dec 3, 2009
Distillery Therapeutics

Indication: Neurology

...in preclinical development to treat SMA. TIK-201 sodium phenylbutyrate, a histone deacetylase (HDAC) inhibitor from Tikvah Therapeutics Inc....
BioCentury | Mar 5, 2009
Distillery Therapeutics

Therapeuticss

...epilepsy. Repligen Corp.'s 4b HDAC inhibitor is in preclinical testing to treat Huntington's disease (HD). Tikvah Therapeutics Inc.'s...
BioCentury | Jan 22, 2009
Distillery Techniques

Technology: Disease models

...validating the results with additional iPS cells from the same patient and in additional patients. Tikvah Therapeutics Inc.'s...
BioCentury | Mar 20, 2008
Cover Story

The 'Smoking Gun' in ALS

...II Teva Copaxone glatiramer acetate Selective major histocompatibility complex (MHC) class II modulator Phase IIB Tikvah Therapeutics Inc....
BioCentury | Aug 27, 2007
Clinical News

TIK-201 regulatory update

...sodium phenylbutyrate, a histone deacetylase (HDAC) inhibitor, from Navinta LLC (Ewing, N.J.) earlier this year. Tikvah Therapeutics Inc....
BioCentury | Aug 13, 2007
Company News

Tikvah Therapeutics management update

Tikvah Therapeutics Inc. , Atlanta, Ga. Business: Neurology Hired: Jack Callicutt as VP and CFO, formerly SVP, CFO and accounting officer at Corautus Genetics Inc. WIR Staff Neurology...
BioCentury | Feb 19, 2007
Company News

Therapade Technologies LLC, Tikvah Therapeutics deal

...LLY, Indianapolis, Ind.) markets Seromycin cycloserine to treat tuberculosis. Therapade Technologies LLC , Williamsburg, Va. Tikvah Therapeutics Inc....
Items per page:
1 - 8 of 8
BioCentury | Dec 12, 2011
Product Development

Back for seconds

...pore ( mPTP ). The other is TIK-201 , a histone deacetylase (HDAC) inhibitor from Tikvah Therapeutics Inc....
...Corp. (NASDAQ:RGEN), Waltham, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel Switzerland SMA Foundation , New York, N.Y. Tikvah Therapeutics Inc....
BioCentury | Dec 3, 2009
Distillery Therapeutics

Indication: Neurology

...in preclinical development to treat SMA. TIK-201 sodium phenylbutyrate, a histone deacetylase (HDAC) inhibitor from Tikvah Therapeutics Inc....
BioCentury | Mar 5, 2009
Distillery Therapeutics

Therapeuticss

...epilepsy. Repligen Corp.'s 4b HDAC inhibitor is in preclinical testing to treat Huntington's disease (HD). Tikvah Therapeutics Inc.'s...
BioCentury | Jan 22, 2009
Distillery Techniques

Technology: Disease models

...validating the results with additional iPS cells from the same patient and in additional patients. Tikvah Therapeutics Inc.'s...
BioCentury | Mar 20, 2008
Cover Story

The 'Smoking Gun' in ALS

...II Teva Copaxone glatiramer acetate Selective major histocompatibility complex (MHC) class II modulator Phase IIB Tikvah Therapeutics Inc....
BioCentury | Aug 27, 2007
Clinical News

TIK-201 regulatory update

...sodium phenylbutyrate, a histone deacetylase (HDAC) inhibitor, from Navinta LLC (Ewing, N.J.) earlier this year. Tikvah Therapeutics Inc....
BioCentury | Aug 13, 2007
Company News

Tikvah Therapeutics management update

Tikvah Therapeutics Inc. , Atlanta, Ga. Business: Neurology Hired: Jack Callicutt as VP and CFO, formerly SVP, CFO and accounting officer at Corautus Genetics Inc. WIR Staff Neurology...
BioCentury | Feb 19, 2007
Company News

Therapade Technologies LLC, Tikvah Therapeutics deal

...LLY, Indianapolis, Ind.) markets Seromycin cycloserine to treat tuberculosis. Therapade Technologies LLC , Williamsburg, Va. Tikvah Therapeutics Inc....
Items per page:
1 - 8 of 8